View more on these topics

Woodford’s Patient Capital to issue more shares

Woodford Neil WIM

Neil Woodford’s Patient Capital Trust will issue more shares to meet demand in the secondary market, as the £800m fund is now 75 per cent invested.

The fund has increased its net asset value per share by 3.1 per cent since its launch on 26 January this year to 101.86p, meaning it has “recouped initial charges and provided a modestly positive return” for investors, says Susan Searle, chair of the Patient Capital Trust board in the trust’s half year results.

The share price on the trust has risen by more than the NAV, now trading at a 11.4 per cent premium. Some of this gain is put down to the company’s inclusion in the FTSE 250 in mid-June, which led to a surge in index tracker buyers.

The board of the investment company has decided to start “tap issuance”, releasing shares at a premium to NAV in order to bolster the secondary market.

“In light of the current premium rating of the company’s shares, the board intends to implement a tap issuance programme…to satisfy excess demand in the secondary market,” says Searle.

The fund is now 75 per cent invested and expects to be fully invested by the end of the year.

The trust is heavily in the biotech industry, which Woodford has pegged as an area of growth. However, he says much of the fund’s performance so far has been delivered by early-stage investments, rather than listed companies.

“Although it is very early days, we are pleased that the company’s net asset value has moved forward modestly,” says Woodford. “Much of the positive performance to date has been delivered by holdings we would classify as early-stage. Indeed, our blue-chip holdings have typically detracted from performance thus far, with GlaxoSmithKline and AstraZeneca in particular showing short-term share price weakness.”

Among the top 10 holdings, which make up almost 34 per cent of the fund, are seven biotech companies, including the largest position in Prothena, a US firm creating immune therapies, followed by Verseon, which aids drug development.

“There is a great deal of enthusiasm in the US biotech sector about new potential treatments for cancer and in other areas of high unmet clinical need, as well as hopes of acquisitions by cash-rich pharmaceutical majors,” says Woodford.



Lee Robertson: Why the IFP/CISI merger gets my vote

A merger between the Chartered Institute of Securities and Investment and the Institute of Financial Planning seems to be on the cards with the announcement today that members are to be consulted on this radical proposal. I have given this a fair amount of thought and should declare an interest here as I am a […]


European and UK equities top picks for advisers in 2015

The appetite for European and UK equities has risen sharply since the start of the year despite geopolitical concerns, experts say. According to the latest Baring Asset Management Investment survey, 86 per cent of respondents said they were either ‘very’ or ‘quite’ favourable towards European equities as an investment opportunity. This is up from 53 per cent […]


Morningstar approves Barnett’s takeover of Woodford’s Invesco funds

Morningstar has given its stamp of approval to Mark Barnett’s role replacing Neil Woodford on two Invesco Perpetual funds – a year after he took on the job. The research firm has bumped the Invesco Perpetual High Income and Invesco Perpetual Income funds up from a neutral to a bronze rating, saying Barnett has proved he can […]


Ian McKenna: The secrets to successful software selection

There seems an unprecedented level of interest among advisers recently for reviewing the technology they use to run their businesses. Consequently, over the coming months this column will mainly focus on how advisers can better prepare for and conduct a review of their software as well as look at a number of the leading systems, […]


News and expert analysis straight to your inbox

Sign up


    Leave a comment


    Why register with Money Marketing ?

    Providing trusted insight for professional advisers.  Since 1985 Money Marketing has helped promote and analyse the financial adviser community in the UK and continues to be the trusted industry brand for independent insight and advice.

    News & analysis delivered directly to your inbox
    Register today to receive our range of news alerts including daily and weekly briefings

    Money Marketing Events
    Be the first to hear about our industry leading conferences, awards, roundtables and more.

    Research and insight
    Take part in and see the results of Money Marketing's flagship investigations into industry trends.

    Have your say
    Only registered users can post comments. As the voice of the adviser community, our content generates robust debate. Sign up today and make your voice heard.

    Register now

    Having problems?

    Contact us on +44 (0)20 7292 3712

    Lines are open Monday to Friday 9:00am -5.00pm